Human Pheromone Sciences Names Additional Director
26 June 2007 - 6:20AM
PR Newswire (US)
SAN JOSE, Calif., June 25 /PRNewswire-FirstCall/ -- Human Pheromone
Sciences, Inc. (OTC:EROX) (BULLETIN BOARD: EROX) ("HPS" or "the
Company") announced today that Mr. Carson Tang was appointed to its
Board of Directors. Mr. Tang currently serves as Managing Partner
to the Renovatio Global Fund, a technology-based fund based in San
Jose, California. He is active in investing in and managing
enterprises in Greater China, including Taiwan, China and
Singapore. Renovatio Global Fund currently holds approximately
655,000 shares (16%) of the Company's Common Stock. In commenting
on the appointment, a Company spokesperson indicated that "we are
very pleased that Carson has agreed to join our Board; he brings a
great deal of experience in financing and investing in
technology-driven companies as well as a wealth of experience in
dealing in the increasingly important Asian markets." Human
Pheromone Sciences, Inc. is a technology-based company, whose
proof-of concept products included prestige-priced fragrances and
toiletries and environmental products sold under the Natural
Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks.
These products contain mood-enhancing compounds, whose efficacy has
been validated at leading universities around the world, and whose
use is covered under United States and foreign patents. The Company
is also involved in research and product development efforts on new
compounds that have been previously identified as stimulating the
emotional centers of the human brain. Further information is
available on line at http://www.erox.com/. The statements in this
news release may contain forward-looking statements that involve
risks and uncertainties that could cause results to differ from
predicted results. Further information on factors that could affect
the Company's results is detailed in the Company's annual report to
shareholders on Form 10-KSB for the year ended December 31, 2006,
and Form 10-QSB for the quarter ended March 31, 2007, as filed with
the Securities and Exchange Commission. The Company undertakes no
obligation to publicly release the result of any revisions to these
forward-looking statements, except as required by law. DATASOURCE:
Human Pheromone Sciences, Inc. CONTACT: William P. Horgan,
Chairman, CEO of Human Pheromone Sciences, Inc., +1-408-938-3030
Web site: http://www.erox.com/
Copyright